Myalept approved for rare fat tissue disorder

(HealthDay)—Myalept (metreleptin for injection) has been approved by the U.S. Food and Drug Administration to treat complications of leptin deficiency for people with the congenital or acquired generalized forms of lipodystrophy.

The disorder is associated with a lack of fat tissue. Leptin, produced by , is a hormone that helps regulate food intake and other hormones such as insulin, the FDA said Tuesday in a news release.

People with lipodystrophy are at greater-than-average risk of developing serious at a young age, making them more prone to out-of-control diabetes and high levels of blood fats called triglycerides.

Myalept was evaluated in a clinical study of 48 people with generalized lipodystrophy and its complications. The trial showed good results in and reduced blood triglycerides, the FDA said.

People taking Myalept may develop a resistance to the drug, making it less effective over time and increasing their risk of severe infection, the agency said.

Less serious side effects could include , headache, weight loss and abdominal pain. The drug is not recommended for people with general obesity.

The FDA said it has ordered a number of post-marketing studies to further evaluate the drug and its potential to cause serious side effects.

Myalept is marketed by Amylin Pharmaceuticals, based in San Diego.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

Blood sugar monitoring system approved for children

Feb 04, 2014

(HealthDay)—U.S. Food and Drug Administration approval of the Dexcom G4 Platinum Continuous Monitoring System has been expanded to include children with diabetes aged 2 years to 17 years, the agency said.

Vimizim approved for rare childhood disorder

Feb 17, 2014

(HealthDay)—Vimizim (elosulfase alfa) has been approved by the U.S. Food and Drug Administration to treat a rare childhood disorder called Mucopolysaccharidosis Type IVA, also known as Morquio A syndrome.

Tretten approved for genetic clotting disorder

Dec 23, 2013

(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.

Northera approved for rare blood pressure condition

Feb 19, 2014

(HealthDay)—Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Stent to treat pancreatic cysts approved

Dec 19, 2013

(HealthDay)—The Axios Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat infected pancreatic cysts that won't drain on their own and could become life threatening, the FDA said ...

Recommended for you

Vaccine proves effective against deadly Middle East virus

Sep 15, 2014

(Medical Xpress)—A vaccine developed by an international team of scientists led by the University of Pittsburgh School of Medicine successfully protects mice against a contagious and deadly virus spreading across the Middle ...

New study looks at improving vaccine awareness

Sep 15, 2014

The best medical therapies won't do much good if the public abstains from using them. Resistance to life-saving interventions may have a variety of root causes, particularly if the biotechnology involved is new and poorly ...

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

User comments